“Patients with small-cell lung cancer derived no survival benefit from cholesterol-lowering medication, according to a phase 3 randomized, double blind, multicenter, placebo-controlled study published in Journal of Oncology.
” ‘There’s no reason for people to stop taking statins to manage their cholesterol, but it’s extremely unlikely, for patients with small-cell lung cancer, that taking statins will make any difference to their cancer treatment outcome,’ Michael J. Seckl, MD, professor of molecular cancer medicine at Imperial College London, said in a press release. ‘Because all statins work in a similar way to lower cholesterol, it’s relatively unlikely that statins other than pravastatin would have a different, more beneficial effect.’ ”
Go to full article.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.
“A diagnosis of high cholesterol is associated with reduced mortality and improved survival in the four most common cancers, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016. The 14 year study from nearly one million patients found that a high cholesterol diagnosis was associated with lower risk of death in lung, breast, prostate and bowel cancers.”
Go to full article.
Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.
“The pace of research in prostate cancer is increasing, and several interesting themes have emerged recently.
“There are provocative data that suggest that the use of statins, the cholesterol-lowering agents, improves prognosis in prostate cancer.
“A team at Dana-Farber Cancer Institute recently reported in JAMA Oncology that, from a series of more than 900 patients with prostate cancer, those on statins had a significant reduction in all-cause and prostate cancer-specific mortality. They also showed preclinical evidence that DHEAS and statins compete for the SLCO2B1 cellular transporter, which facilitates their entry into prostate cells, thus providing a potential mechanism of action.”
“Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn’t take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.
“In a study published online today by JAMA Oncology, the researchers report that men who had been taking statins since the start of androgen deprivation therapy (ADT) went a median of 27.5 months before their disease began to worsen, compared to 17.4 months for men who didn’t take statins. The trial involved 926 patients, 70 percent of whom had their disease progress during a six-year period.
“ ‘This median 10-month benefit in delaying disease progression suggests that statins could be a valuable addition to our current therapies for prostate cancer,’ says the study’s first author, Lauren Harshman, MD, medical oncologist at the Lank Center for Genitourinary Oncology at Dana-Farber. ‘These results are supported by multiple prior epidemiologic studies demonstrating that statin use may be associated with improved outcomes in prostate cancer, but require validation.’ “
“Cholesterol-lowering statin drugs may slow down prostate cancer in men who are also taking medication to reduce their levels of male hormones, according to new research.
“Taking a statin alongside androgen deprivation therapy slowed the progress of prostate cancer by about 10 months, said the study’s lead author, Dr. Lauren Christine Harshman, an assistant professor at Dana-Farber Cancer Institute and Harvard Medical School.
” ‘Patients on a statin have a significantly longer time to progression,’ Harshman said.
“The study’s findings were presented recently at a meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. Research presented at meetings is generally viewed as preliminary until published in a peer-reviewed journal.
“The study did not prove a cause-and-effect link between statins and prostate cancer survival, just an association.”
“Stopping statins for terminal patients doesn’t hasten death and may improve their quality of life, a trial showed.
“The 60-day mortality rate didn’t differ significantly after discontinuation of long-standing statin therapy compared with staying on it (23.8% versus 20.3%, P=0.60), Amy Abernethy, MD, PhD, of Duke University Medical Center, and colleagues found.”